OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™
Stockholm, February 7, 2024 – OncoZenge AB (publ) today announces that the company has filed a new patent application with the Swedish Patent and Registration Office (PRV). The patent strengthens the protection of the second generation of BupiZenge™ and the innovations made in connection with the recent reformulation. The new patent will provide strengthened IP protection for strategic partners and licensees upon approval.In line with OncoZenge's strategy, the company has assessed the opportunities for complementary patents that further strengthen the protection for the second generation